Mangalam Drugs And Organics Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2012 • Bulk Drugs: 100.0%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Working capital cycle has improved - days down from 12 to 8
CONS
- Receivables are growing faster than sales - a possible quality concern
- Promoter holding has decreased over last 2 years: -14.7pp
- Interest coverage is weak at 1.3x - earnings barely cover interest
- Company's return on assets is weak at 1.9%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| MANGALAM | 36.37 | 0.00 | 57.57 | 0.00 | -7.64 | 44.64 | 57.12 | -0.16 | 8.55 | 1.58 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 97 | 102 | 76 | 80 | 89 | 73 | 57 | 49 | 58 | 67 | 57 | |
| 90 | 91 | 68 | 71 | 80 | 63 | 62 | 52 | 60 | 73 | 64 | |
| Operating Profit | 7 | 11 | 8 | 9 | 9 | 10 | -5 | -3 | -2 | -6 | -7 |
| OPM % | 6.89% | 11.18% | 10.67% | 10.67% | 9.72% | 13.60% | -8.08% | -6.33% | -2.64% | -8.35% | -12.01% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 3 | 4 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 4 |
| Profit before Tax | 0 | 4 | 1 | 1 | 1 | 2 | -13 | -12 | -10 | -13 | -7 |
| Tax % | -1150.00% | 10.18% | -362.07% | -124.17% | 5.84% | 96.34% | -6.15% | 41.06% | -0.00% | -1.13% | -13.24% |
| Net Profit | 0 | 0 | 3 | 3 | 1 | 0 | -14 | -7 | -10 | -13 | -8 |
| 0.31 | 2.23 | 1.70 | 1.70 | 0.81 | 0.04 | -8.72 | -4.64 | -6.21 | -8.48 | -4.83 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 369 | 318 | 232 | |
| 351 | 282 | 249 | |
| Operating Profit | 17 | 36 | -17 |
| OPM % | 4.71% | 11.26% | -7.39% |
| 0 | 1 | 0 | |
| Interest | 14 | 15 | 16 |
| Depreciation | 15 | 17 | 18 |
| Profit before Tax | -11 | 5 | -42 |
| Tax % | 18.08% | -40.43% | 9.63% |
| Net Profit | -9 | 7 | -38 |
| EPS | -5.73 | 4.25 | — |
| Dividend Payout % | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- -14%
- 5 Years:
- -24%
- 3 Years:
- -30%
- 1 Year:
- -53%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- Last Year:
- 5%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 16 | 16 |
| 120 | 133 | |
| 96 | 88 | |
| Trade Payables | 66 | 91 |
| 35 | 38 | |
| Total Liabilities | 334 | 366 |
| 148 | 163 | |
| 124 | 139 | |
| 28 | 39 | |
| Cash & Bank | 1 | 3 |
| 33 | 23 | |
| Total Assets | 334 | 366 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 4 | 43 | |
| Cash from Investing | -12 | -19 |
| Cash from Financing | 5 | -22 |
| -3 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-01 - Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-31 - Mangalam Drugs And Organics Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026
2026-08-17 - Mangalam Drugs And Organics Limited has informed the Exchange about Fraud/Default/Arrest
2026-08-13 - Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-12 - Mangalam Drugs And Organics Limited has informed the Exchange regarding Change in Auditors of the company.
2026-08-12 - Mangalam Drugs And Organics Limited has informed the Exchange regarding Change in Auditors of the company.
2026-08-12 - Mangalam Drugs And Organics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-06 - Mangalam Drugs And Organics Limited has informed the Exchange about General Updates
2026-07-16 - Mangalam Drugs And Organics Limited has informed the Exchange about Fraud/Default/Arrest
News
Recent coverage and analyst commentary for MANGALAM
Loading news…
AI Stock Analyst
Mangalam Drugs And Organics Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account